Romosozumab

• CAT Number: I042720
• CAS Number: 909395-70-6
• Purity: ≥95%

Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis[1][2].
Romosozumab (30 mg/kg; s.c. twice a week for 10 weeks) converts trabecular rods into trabecular plates in cynomolgus monkeys[1].
Romosozumab (3 and 30 mg/kg; s.c. once a week for 6 or 12 months) improves bone mass,
architecture, and bone strength, and maintains bone quality at the same time in mature cynomolgus monkeys with 4 months post-ovariectomy[2].

Reference

[1]. Paik J, Scott LJ. Romosozumab: A Review in Postmenopausal Osteoporosis. Drugs Aging. 2020 Nov;37(11):845-855.
 [Content Brief]

[2]. Ominsky MS, et al. Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys. J Bone Miner Res. 2017 Apr;32(4):788-801.
 [Content Brief]